Vanda Pharmaceuticals Secures FDA Approval to Expand Use of Tradipitant for Motion Sickness

Vanda Pharmaceuticals Receives FDA Approval to Expand Clinical Use of Tradipitant

Vanda Pharmaceuticals Inc. announces a significant milestone in its clinical development journey as the U.S. Food and Drug Administration (FDA) lifts the partial clinical hold on its investigational drug, tradipitant. This decision allows the company to extend the administration of tradipitant beyond the previously imposed limit of 90 doses, enhancing its potential as a treatment for motion sickness. The FDA's decision follows a formal dispute resolution request from Vanda and an expedited review by the Center for Drug Evaluation and Research (CDER), which affirmed the company's definition of motion sickness as an acute condition. This pivotal ruling positions tradipitant to be utilized as an event-driven therapy without the necessity for an additional six-month dog toxicity study, thus accelerating its path toward wider clinical application.

The lifting of the hold not only paves the way for expanded clinical studies on motion sickness but also keeps Vanda's timeline for the New Drug Application (NDA) review on track. The FDA's Prescription Drug User Fee Act (PDUFA) target action date for tradipitant, which aims to prevent vomiting induced by motion, is set for December 30, 2025. If approved, tradipitant is poised to become the first new pharmacologic treatment for motion sickness in over four decades, a noteworthy advancement in a field that has seen little innovation. Vanda's President and CEO, Dr. Mihael H. Polymeropoulos, expresses appreciation for the FDA's expedited review, emphasizing the collaborative efforts that led to this positive outcome.

Tradipitant's development reflects Vanda Pharmaceuticals' commitment to addressing unmet medical needs through innovative therapies. In addition to motion sickness, tradipitant is under investigation for several other conditions, including gastroparesis and nausea and vomiting associated with GLP-1 receptor agonists. This multi-faceted approach signifies Vanda's strategic intent to diversify its therapeutic applications and enhance patient care across various indications.

In light of these recent developments, Vanda Pharmaceuticals solidifies its position as a key player in the pharmaceutical industry, particularly in the realm of motion-related therapies. The FDA's decision not only marks a victory for Vanda but also heralds a new era for patients seeking effective treatments for motion sickness. As the company continues to navigate the regulatory landscape, its focus remains firmly on delivering innovative solutions that meet the evolving needs of patients worldwide.